Wednesday, March 29, 2017

Antiva Biosciences Raises $22M

South San Francisco-based Antiva Biosciences, a biopharmaceuticals startup targeting treatments for pre-cancerous lesions caused by human papilloma virus (HPV) infection, said it has raised $22M in a Series C funding. The funding was led by Brace Pharma Capital, an also included NS Investment, Osage University Partners and Alexandria Venture Investments, plus Canaan Partners and Sofinnova Ventures. Vinzenz Ploerer of Brace Pharma has joined the company's board with the new funding. Gail Maderis is President and CEO of Antiva. The company just initiated its first Phase 1 clinical studies. More information »